Fat loss & metabolic peptides

Metabolic and fat-loss peptide protocols — AOD-9604, 5-Amino-1MQ, Tesamorelin. Titration schedules, dose ranges, cycle length, side effects.

Fat-loss peptides fall into two groups: appetite- and gastric-emptying modulators, and lipolytic fragments such as AOD-9604. Metabolic protocols are titrated upward slowly over weeks to limit gastrointestinal side effects.

Category overview

Target visceral fat, regulate appetite, and improve insulin sensitivity for sustainable body composition changes.

Protocols at a glance

Peptide	Dose range	Frequency	Cycle
AOD-9604	250 – 1000 mcg	Daily (AM fasted) or split AM/PM	12 weeks on, 4 weeks off
Tesamorelin	1 – 2 mg	Daily (bedtime)	26-week cycles typical; continuous with monitoring
5-Amino-1MQ	5 – 15 mg	1× daily, subcutaneous injection	8–12 weeks on, 4 weeks off

AOD-9604 — GH Fragment 177-191

Modified fragment of human growth hormone specifically designed for fat loss without GH side effects. Targets adipose tissue directly; excellent for stubborn fat areas.

• Dose range: 250 – 1000 mcg. Frequency: Daily (AM fasted) or split AM/PM. Cycle: 12 weeks on, 4 weeks off.
• Reconstitution: 2mg → 1ml bacteriostatic water
• Reconstitution: 5mg → 1ml bacteriostatic water
• Reconstitution: 10mg → 2ml bacteriostatic water
• Targets stubborn fat deposits (abdomen, thighs, love handles)
• No GH side effects (no blood sugar changes, no hunger)
• Bonus cartilage and joint repair properties
• Anti-obesity mechanism without muscle catabolism
• No blood sugar changes; no hunger spike.
• Stacks: Ipamorelin (GH support), Frag 176-191

Tesamorelin — Egrifta

FDA-approved GHRH analog specifically for reducing visceral adipose tissue. Originally developed for HIV-associated lipodystrophy; excellent for stubborn belly fat.

• Dose range: 1 – 2 mg. Frequency: Daily (bedtime). Cycle: 26-week cycles typical; continuous with monitoring.
• Reconstitution: 2mg → 1ml bacteriostatic water
• Reconstitution: 5mg → 2ml bacteriostatic water
• Reconstitution: 10mg → 2ml bacteriostatic water
• FDA-approved specifically for visceral fat reduction
• Up to 18% reduction in trunk fat in clinical trials
• Improves triglycerides and liver fat content
• Stimulates natural GH without suppression
• Effects plateau after 6–9 months.
• Stacks: Ipamorelin (GH amplification), AOD-9604 (localized fat loss), CJC-1295

5-Amino-1MQ

NNMT inhibitor that enhances cellular energy expenditure and fat metabolism. Novel mechanism targeting the NAD+ salvage pathway; administered subcutaneously for improved bioavailability and consistent dosing.

• Dose range: 5 – 15 mg. Frequency: 1× daily, subcutaneous injection. Cycle: 8–12 weeks on, 4 weeks off.
• Reconstitution: 5mg → 0.5ml bacteriostatic water
• Reconstitution: 10mg → 1ml bacteriostatic water
• Reconstitution: 15mg → 1.5ml bacteriostatic water
• Reconstitution: 20mg → 2ml bacteriostatic water
• Inhibits NNMT enzyme to boost cellular metabolism
• Increases NAD+ levels for enhanced energy production
• Promotes fat cell death (adipocyte apoptosis)
• May reverse age-related metabolic dysfunction
• Subcutaneous injection — rotate sites (abdomen, thigh, flank).
• Novel compound; conservative cycling recommended.
• Best taken in the morning to align with circadian metabolism.
• Stacks: NMN/NR (NAD+ synergy), MOTS-c

Safety principles

• Start Low, Go Slow: Always begin with the minimum effective dose and titrate gradually over weeks.
• Get Baseline Bloodwork: Before starting, obtain labs including CBC, CMP, lipid panel, hormone panel (testosterone, estrogen, IGF-1, GH), fasting insulin, HbA1c, liver enzymes, and inflammatory markers.
• Monitor Regularly: Retest labs every 4–8 weeks. Track subjective markers daily (sleep, energy, mood, appetite, injection site reactions).
• Source Responsibly: Only use peptides from reputable compounding vendors with third-party COA testing. We STRONGLY recommend they also are based out of the USA for quality assurance.
• Recognize Warning Signs: Stop immediately and seek medical attention for severe injection site reactions, difficulty breathing, chest pain, severe headache, vision changes, or allergic reactions.
• Drug Interactions: Many peptides interact with insulin, diabetes drugs, blood thinners, immunosuppressants, and hormonal therapies.
• Contraindications: Not for pregnant/breastfeeding women, individuals under 18, those with active cancer, severe liver/kidney disease, or uncontrolled diabetes.

Important

All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.